U.S. markets closed

Assertio Holdings, Inc. (ASRT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.4400+0.0800 (+2.38%)
At close: 04:00PM EST
3.4400 0.00 (0.00%)
After hours: 07:50PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Bottom Triangle

Bottom Triangle

Previous Close3.3600
Bid3.4000 x 1100
Ask3.4200 x 1300
Day's Range3.3550 - 3.4800
52 Week Range1.2600 - 4.4400
Avg. Volume691,477
Market Cap166.13M
Beta (5Y Monthly)1.66
PE Ratio (TTM)6.25
EPS (TTM)0.5500
Earnings DateMar 07, 2023 - Mar 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.94
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
29% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ASRT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Assertio Holdings, Inc.
    ASRT: Raising target price to $0.648000ASSERTIO THERAPEUTICS INC has an Investment Rating of SELL; a target price of $0.648000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    3 years agoArgus Research
View more
  • GlobeNewswire

    Assertio Increases Full-Year Net Product Sales Outlook to in Excess of $152 Million

    LAKE FOREST, Ill., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it is raising its outlook for 2022 full-year net product sales to greater than $152 million, increased from its prior outlook calling for net product sales of greater than $141 million for the full year. The Company noted that net product sales to date in the fourth quarter

  • Zacks

    Are Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?

    Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Assertio (ASRT) have performed compared to their sector so far this year.

  • Zacks

    Assertio (ASRT) Q3 Earnings and Revenues Top Estimates

    Assertio (ASRT) delivered earnings and revenue surprises of 14.29% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?